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Abstract
Loss of the short arm of chromosome 3 (3p) occurs early in >95% of clear cell renal cell 
carcinoma (ccRCC). Nearly ubiquitous 3p loss in ccRCC suggests haploinsufficiency for 3p tumor 
suppressors as early drivers of tumorigenesis. We previously reported methyltransferase SETD2, 
which trimethylates H3 histones on lysine 36 (H3K36me3) and is located in the 3p deletion, to 
also trimethylate microtubules on lysine 40 (αTubK40me3) during mitosis, with αTubK40me3 
required for genomic stability. We now show that mono-allelic, Setd2-deficient cells retaining 
H3K36me3 but not αTubK40me3 exhibit a dramatic increase in mitotic defects and micronuclei 
count with increased viability compared to bi-allelic loss. In SETD2-inactivated human kidney 
cells, rescue with a pathogenic SETD2 mutant deficient for microtubule (αTubK40me3) but not 
histone (H3K36me3) methylation replicated this phenotype. Genomic instability (micronuclei) 
was also a hallmark of patient-derived cells from ccRCC. These data show the SETD2 tumor 
suppressor displays a haploinsufficiency phenotype disproportionately impacting microtubule 
methylation and serves as an early driver of genomic instability.
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Introduction
Many cancer types are characterized by large scale, characteristic alterations of 
chromosomal copy number. Clear cell renal cell carcinoma (ccRCC) is characterized by 
frequent inactivating mutations of the Von Hippel–Lindau (VHL) tumor suppressor gene (1), 
with accompanying loss of heterozygosity provided by a large deletion of chromosome 3p 
(2). Recent large-scale multiplatform sequencing techniques identified that, in addition to 
VHL, other tumor suppressor genes encoding epigenetic regulators such as Polybromo 1 
(PBRM1/BAF180), BAP1, and Set domain containing 2 (SETD2) are implicated in ccRCC 
tumorigenesis (3–5). Importantly, all of these commonly mutated genes reside in the same 
portion of affected chromosome 3p. Loss of 3p results in loss of heterozygosity (LOH) for 
all four of these genes, which individually acquire “second-hit” mutations and loss of 
function of the remaining allele in subsets of ccRCC. Of these, SETD2 is of particular 
interest, as this tumor suppressor has been increasingly identified as a common mutation 
across cancer types, including lung (6), bladder (7), glioma (8) and leukemia (9).
SETD2 encodes a methyltransferase known to be the sole enzyme responsible for the 
trimethylation of lysine 36 on histone H3 (H3K36me3) (7, 8, 10–12). Bi-allelic deficiency of 
SETD2 via deletions and inactivating mutations occur in up to 20% of primary human RCC 
tumors and it is associated with more advanced disease and the metastatic phenotype, 
typically lethal within 1–5 years (13). Bi-allelic loss of SETD2 has been shown to result in 
loss of H3K36me3 in ccRCC-derived cells and tumors (9, 14, 15). Examination of 
H3K36me3 status in ccRCC cells of metastatic tumor specimens suggest that SETD2 
mutations may occur in over 50% of metastatic lesions (16). Furthermore, a study of ccRCC 
intratumoral heterogeneity identified distinct SETD2 mutations across subsections of an 
individual tumor, suggesting a selection bias for SETD2 mutation in the course of ccRCC 
development (7).
SETD2 is a multi-domain containing protein with distinct functions for each domain. The 
methyltransferase activity is mediated by a centrally-located SET domain. Mutations in this 
domain are common in ccRCC (10, 14), suggesting loss of catalytic activity is a critical 
event in tumor development. We previously characterized a pathogenic SET domain 
mutation found in ccRCC, an arginine-to-cysteine mutation at residue 1625 of SETD2 
(R1625C) (15), which abolishes methylation activity. At its C-terminus, SETD2 also 
contains the Set2-Rpb1-interaction (SRI) domain (17). This domain mediates the interaction 
between SETD2 and the phosphorylated C-terminal domain of RNA polymerase II 
(RNAPII). We also identified a recurrent mutation in the SRI domain, an arginine-to-
histidine mutation at residue 2510 (R2510H) (15). This mutation preserves the H3 
trimethylation catalytic activity of SETD2, suggesting SETD2 may have other key functions 
in addition to its to the well-characterized role as a histone methyltransferase.
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We recently discovered that SETD2 also functions as a microtubule methyltransferase, in 
addition to the well-characterized role of SETD2 in histone methylation (18). SETD2 
trimethylates α-tubulin on lysine 40 (αTubK40me3) of microtubules and loss of this mark 
results in genomic instability. SETD2-null cells exhibit mitotic spindle and cytokinesis 
defects, polyploidy, and formation of micronuclei. Importantly, pathogenic SETD2 
mutations in the SET domain as well as the SRI domain were unable to methylate 
microtubules, and caused an increase in chromosome bridges and lagging chromosomes 
relative to wild-type SETD2, indicating that in addition to the catalytic domain, a functional 
SRI domain was also required for αTubK40me3 (18).
These mitotic alterations caused by loss of αTubK40me3 can lead to chromosomal 
abnormalities and genomic instability, hallmarks of tumorigenesis, and are thought to be an 
important source of genetic diversity and development of cell clones during tumor 
progression (19). In the case of the type of defects observed with SETD2 mutants deficient 
in microtubule methylation (lagging and bridging chromosomes), this genomic instability 
results in the formation of micronuclei. Micronuclei contain acentric chromosome 
fragments, acentric chromatid fragments, or whole chromosomes that failed to migrate 
during mitosis, which are enclosed by nuclear membrane (20). The presence of micronuclei 
is a reliable cytological indicator of chromosome instability (21), and micronuclei are a 
common feature of many solid tumors and pre-neoplastic lesions (19,20), but have not been 
studied in any detail in ccRCC to date.
Here, we report that SETD2’s ability to trimethylate microtubules and preserve genomic 
stability is dose dependent, and SETD2 haploinsufficiency or reduced dosage, is sufficient to 
impair genomic stability and induce micronuclei formation. Using micronuclei as a readout 
of genomic instability in wild-type (WT) SETD2 and SETD2 disrupted human kidney 
proximal tubule epithelial cells (HKC), we confirmed that SETD2 loss causes a significant 
increase in micronuclei. To directly demonstrate that SETD2 haploinsufficiency was 
sufficient to induce genomic instability (micronuclei), we induced loss of a single copy of 
Setd2 using Setd2w/f mouse embryonic fibroblasts (MEFs). Mono-allelic loss of Setd2 was 
sufficient to increase lagging and bridging chromosomes, and caused a significant increase 
in micronuclei formation. Importantly, while promoting micronuclei accumulation, mono-
allelic SETD2 loss had no measurable effect on H3K36me3, but did cause loss of 
αTubK40me3, revealing a previously unrecognized effect of SETD2 dosage. Comparing 
different SETD2 mutations, we also found that the SRI-domain mutation, which rescues 
H3K36me3, but not αTubK40me3, fails to rescue micronuclei formation and mitotic defects 
in SETD2-deleted cells compared to WT SETD2. Importantly, micronuclei were also a 
common feature of 3p deleted ccRCC cell lines and were seen in a significant fraction of 
tumor cells from all patients with ccRCC. These data indicate that SETD2 is 
haploinsufficient for αTubK40 trimethylating activity, with loss of microtubule methylation 
driving early genomic instability in tumors with 3p loss, preceding the loss of histone 
H3K36 trimethylation, and contributing to the progression of ccRCC. Moreover, our results 
shed light on a new mechanism by which mono-allelic inactivation of SETD2 or 3p loss can 
drive tumorigenesis in other cancers, and points to microtubule methylation as a key tumor 
suppressive activity of SETD2.
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Human renal cell carcinoma ACHN, UMRC2, Caki-1, and A498 cells were acquired from 
the American Type Culture Collection (Manassas, VA). RCC4 cells were generously 
provided by Dr. William Kim (UNC, Chapel Hill, NC). The SV-40 transformed human renal 
tubule epithelial cell line (HKC) was obtained from Dr. Lorraine Racusen, Baltimore, MD. 
All cells undergo annual STR confirmation. Human cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM, Gibco/Life Technologies, Carlsbad, CA) supplemented 
with 10% FBS (Gemini Bio-Products, West Sacramento, CA), non-essential amino acids, L-
glutamine, penicillin, and streptomycin. For Setd2w/f and Setd2f/f mouse embryonic 
fibroblasts, cells were maintained in phenol-red free media (DMEM, high glucose, HEPES, 
no phenol red) supplemented with Sodium Pyruvate and GlutaMAX (ThermoFisher 
Scientific), to prevent any spontaneous activation of the Cre recombinase by estrogenic 
compounds found in phenol red containing media. All cultures were maintained at 37°C in 
5% CO2. The identify of all human cell lines employed in the present study has been 
authenticated using the Short Tandem Repeat (STR) profiling test offered by ATCC as a 
service. All cell lines have been tested for Mycoplasma contamination using the PCR-based 
ATCC’s Universal Mycoplasma Detection test (catalog number: 30-10102K).
Generation of Setd2w/f and Setd2f/f mouse embryonic fibroblasts (MEFs)
The detailed information for generating Setd2w/f and Setd2f/f MEFs was described in a 
previous publication (18). In brief, Setd2w/f or Setd2f/f MEFs were generated from 13.5 days 
postcoitum (d.p.c.) embryos of Setd2w/f or Setd2f/f mice, respectively. The cells were 
spontaneously immortalized via serial passaging. The immortalized cells were transfected 
with an ER-Cre vector expressing Cre recombinase fused with a mutated ligand-binding 
domain for the human estrogen receptor (ER-Cre). Stable cell lines expressing ER-Cre were 
generated by selection using 5μg/ml blasticidin (Thermo Fisher Scientific).
Setd2w/f or Setd2f/f MEFs expressing ER-Cre were treated with 3μM 4-hydroxytamoxifen 
(4-HT, the active metabolite of tamoxifen, Sigma-Aldrich) or vehicle (0.01% ethanol) for 
two days (or as indicated) for efficient Setd2 knockout. The phenotype of Setd2w/f MEFs is 
similar to that observed with bi-allelic loss (Setd2f/f) (18), for which micronuclei were 
counted after two days of tamoxifen treatment, while the Setd2w/f MEFs remain viable as a 
culture for several passages.
Generation of SETD2-null or mutation human kidney epithelial cells
To establish HKC SETD2 null cells, HKC cells were transfected as previously described 
(15) with a pair transcription activator-like effector nucleases (TALENs) constructs targeting 
exon 3 (5′-TCATGTAACATCCAGGCC-3′ and 5′-ACAGCAGTAGCATCTCCA-3′) using 
Amaxa cell Line Nucleofector Kit V (Lonza, Basel, Switzerland) and single cell sorted to 
isolate single clones. Individual clones were screened for loss of H3K36me3 and sequenced 
at the SETD2 target site to confirm the presence of inactivating mutations. The allelic 
sequencing confirmed the SETD2 inactivation through frameshift mutations at the TALEN 
target site in both SETD2 alleles.
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Generation of SETD2 knockdown human kidney epithelial cells
HKC cells were infected with shRNA virus expressing either a Scramble (SCR) or shRNA 
against SETD2 (TRCN0000237839, Sigma). shSETD2 sequence obtained from the Broad 
Institute shRNA Library. Cells were passaged 24 hours post infection in media containing 
puromycin (1ug/ml). Following drug selection, cells were passaged once more at day 3 post 
shRNA virus infection. Subsequently, cells were fixed with either paraformaldehyde or 
methanol for immunostaining at 6 days post infection.
SNP array and 3p structural variation analysis
Genomic DNA was isolated from confluent 10cm plates using the Qiagen DNeasy Blood & 
Tissue Kit (Qiagen 69504) per manufacturer’s standard protocols. SNP array was conducted 
on the Infinium Core-24 kit BeadChip (Illumina) by UNC Mammalian Genotyping Core 
according to manufacturer’s standard protocols. The SNP data was pre-processed with 
Genomestudio v2 (Illumina) and the R package, genoCNV was used to estimate the copy 
number states and genotype calls for all interested cell lines. The allele-specific copy 
number analysis of tumors (ASCAT) algorithm (22) (version 2.5) was employed to calculate 
somatic whole-genome allele-specific copy number profiles (ASCAT-profiles), as well as 
estimates of cell ploidy.
Western Blot
Cells were lysed by gentle pipetting several times and incubated on ice for 10 mins in a cell 
fractionation buffer (320 mM sucrose, 10mM Tris-HCl (pH8.0), 2mM magnesium acetate, 3 
mM calcium chloride, 0.1 mM EDTA, 0.5% NP-40, fresh 1mM dithiothreitol, protease 
inhibitor cocktail, 1 mM PMSF, and 1 mM sodium orthovanadate). Cytoplasmic fractions 
were collected after centrifugation at 1,000 g for 5 min and were used for western blots 
using antibodies against α-TubK40me3 (18, 23) or α-tubulin (MA1-19162, Thermo Fisher 
Scientific, Waltham, MA). The nuclear proteins were extracted in cell lysis buffer (20 mM 
Tris-HCl (pH7.5), 150 mM NaCl, 1mM EDTA, 1 mM EGTA, 1% Triton X-100, and 
protease inhibitor cocktail) by sonication for 3 cycles of 30 secs on/off using Bioruptor 300 
(Diagenode, Denville, NJ) and used for western blots using antibodies against SETD2 
(HPA042451, Sigma-Aldrich, St. Louis, MO), H3K36me3 (61101, Active Motif, Carlsbad, 
CA) or histone H3 (ab1791, Abcam, Cambridge, MA). The samples were separated on a 4–
15% SDS-PAGE gel and transferred onto a PVDF membrane. Membranes were blocked in 
5% non-fat milk in TBST (50 mM Tris pH 7.5, 150 mM NaCl, and 0.1% Tween 20) for 1 hr 
and immunoblotted using primary antibodies for overnight and secondary goat anti-mouse 
IgG-HRP (sc-2005, Santa Cruz Biotechnology, Dallas, TX) or goat anti-rabbit IgG-HRP 
(sc-2004, Santa Cruz Biotechnology) for 2 hrs.
For SETD2 knockdown HKC cells, lysates were separated on a 4–15% SDS-PAGE gel and 
the proteins were subsequently transferred to a PVDF membrane. Membranes were blocked 
in 5% non-fat milk in TBST and incubated O/N with primary antibodies in milk. Anti-β-
Tubulin (05-661, EMD Millipore) antibody was used as loading control.
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Immunofluorescence staining for micronuclei
HKC cells were cultured on chamber slides (Corning) for 16–18 hours and fixed using a 4% 
para-formaldehyde for 15 minutes. After three washes with cold PBS for 5 minutes each, the 
samples were permeabilized using a 0.25% Triton X-100 in PBS for 10 minutes and 
followed by 10-minute incubation with 1% hydrogen peroxide. After blocking in 5% BSA, 
cells were incubated at 4°C overnight with mouse anti LAP2 (1:500, Abcam) or human anti-
CREST (1:6000, Antibody Inc) primary antibody. After four rounds of vigorous washing for 
10 minutes each using PBST, cells were incubated for 1 hour at room temperature with goat 
anti-mouse IgG Alexa488 (Life technologies, 1:1000) and goat anti-human IgG H+L 568 
(Life technologies, 1:1000) secondary antibody. After washing, cells were counterstained 
using DAPI for subsequent visualization of nuclei. Coverslips were mounted into chamber 
slides with ProLong Gold Antifade Mountant (Life technologies). Fluorescence signals were 
visualized using confocal microscopy (LSM 880, Zeiss). The number of micronuclei per 300 
cells was counted and repeated for two times per coverslip. Data from three different 
coverslips in three independent experiments were manually quantitated.
For shRNA SETD2 knockdown of HKC cells, samples were fixed with cold methanol for 5 
min at −20C, followed by three 5 min washes in PBS. Cells were then blocked in 2.5% 
BSA, 1% normal goat serum (NGS) in PBS for 1 hr followed by incubation with anti-
LaminB1 (ab16048, Abcam) (1:250) antibody in PBS-BSA-NGS for 1 hr at RT. Cells were 
washed with PBS-0.1% Tween 20-NGS (PBST-NGS), followed by secondary antibody 
incubation for 30 min at RTπ. Cells were counterstained using DAPI (1:1000) for 5 min and 
then mounted on slides using Prolong Gold Antifade mounting media. Images were acquired 
on a Zeiss 800 Upright confocal microscope using a 63x/1.4 NA under default filter settings 
and pinhole of 1 airy unit. For every image, approximately ten Z-sections were acquired 
with an average of 0.4um thickness per slice. Z-stacks were processed in FIJI (Version 2.0.0) 
and images presented are maximum intensity projections of Z-stacks. The number of 
micronuclei per 150 cells per sample (shScramble and shSETD2) was counted and data from 
three independent experiments were manually quantitated.
Setd2 knockout was induced in MEFs (as described above), then fixed in 3.7% 
formaldehyde solution for 15 minutes, permeabilized in Triton-X 100 for 20 minutes and 
incubated for an hour in blocking buffer containing 3% bovine serum albumin (BSA) in 
1XPBS at room temperature (RT). MEFs were then probed with human anti-CREST 
antibody (Antibody Inc) and anti-rabbit CENPB (Abcam, ab25734) for an hour at RT. 
Alexafluor 568- and 488-conjugated secondary antibodies (Invitrogen) were used to detect 
anti-CREST and anti-CENPB respectively while DNA was stained using Hoechst 33342 
(Invitrogen). Immunoflourescence images were taken using Zeiss Axiovert 200M-inverted 
Microscope equipped with epifluorescence optics and an Apotome structured illumination 
module (Carl Zeiss) or a 60X 1.4 NA objective (Olympus) on a DeltaVision Elite imaging 
system (GE Healthcare) equipped with a Cool SnapHQ2 CCD camera (Roper), and 
processed using ratio deconvolution in SoftWorx (GE Healthcare). Total CREST (+) 
micronuclei were counted per 100 micronuclei per coverslip from three independent 
experiments.
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Immunofluorescence staining for mitotic defects
Cells were cultured on cover slips and fixed using ice cold Methanol for 10 minutes and 
followed by permeabilization using a 0.2% Triton X-100 solution in PBS buffer for 5 
minutes. After three washes using PBS buffer, the cells were blocked in 2% BSA blocking 
buffer for 30 minutes at RT. Cells were incubated in blocking buffer using primary 
antibodies overnight at 4°C. Primary antibodies were diluted as follows; rabbit anti-
H3K36me3 (1:1000, Abcam), mouse anti-α-tubulin (1:400, clone DMIA, Sigma) and 
human anti-centromere (1:6000, Antibody Inc). After five rounds of vigorous washing for 
10 minutes each using PBST, cells were incubated for 1 hour in blocking buffer with 
corresponding secondary antibodies (donkey anti-rabbit (clone 488, Life technologies), goat 
anti-mouse IgG H&L Cy5 (Abcam) and goat anti-human IgG H+L (clone 568, Life 
technologies) at a dilution of 1:1000. Following more than three washes, for 10 minutes each 
using PBST, cells were counterstained using DAPI for subsequent visualization of nuclei. 
Coverslips were mounted in ProLong Gold Antifade Mountant (Life technologies) and cells 
visualized using confocal microscopy (LSM 880, Zeiss).
Immunofluorescence staining for micronuclei in human ccRCC
Human primary RCCs were obtained under an approved IRB protocol with patients 
providing written informed consent to de-identified use of tissue. The studies were 
conducted in accordance with recognized ethical guidelines (e.g., Belmont Report).
Approval was granted by the Vanderbilt Biomedical IRB. Following pathological 
assessment, extra tissue is freshly provided, cells were dispersed by mechanical dissociation, 
followed by enzymatic digestion using collagenase and DNase. Single cell suspension was 
passed over 70μm strainer then subjected to red blood cell lysis. Samples were then mounted 
with Wescor Cytopro cytocentrifuge and fixed with 4% PFA (Electron Microscopy Sciences) 
in Cytoskeleton Buffer (10mM MES pH6.1, 138mM KCl, 3mM MgCl2, 2 mM EGTA, 
320mM sucrose) for 10 minutes. Cells were permeabilized with 0.1% TritonX-100 in PBS 
(PBSTx), blocked with 1% BSA in PBSTx, stained for pan-cytokeratin (AE1/AE3+5D3, 
Abcam ab86734, 1:100 in 1% BSA in PBSTx) and DAPI, then mounted with Prolong Gold 
Antifade reagent (Thermo Fisher Scientific). For secondary antibody staining, Alexa Fluor® 
488 AffiniPure Donkey Anti-Mouse IgG (Jackson ImmunoResearch, 715-545-151, 1:500) 
was used. Images were acquired on a Zeiss LSM880 or LSM710 confocal microscopes 
using 63x/1.40 Plan-Apochromat oil objective and 405nm and 488nm lasers, default filter 
settings and pinhole of 1 airy unit or Deltavision Elite Imaging System. Images were 
processed in FIJI (Version 2.0.0) and images presented are maximum intensity projections of 
individual cells.
Immunohistochemistry
For H3K36me3 immunohistochemistry (IHC), patient de-identified, formalin fixed and 
paraffin (FFPE) embedded ccRCC samples were sectioned and hematoxylin and eosin 
(H&E) stained by Vanderbilt University Medical Center Translational Pathology Shared 
Resource. To perform H3K36me3 immunohistochemistry, FFPE sections were 
deparaffinized, then incubated for 45 minutes in heated citric acid buffer (10mM citric acid, 
0.05% Tween-20, pH 6.o) for antigen retrieval. Slides were then stained with H3K36me3 
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antibody (Abcam, ab9050, 1:500), using the Cell and Tissue Staining Kit (Rabbit, HRP-
DAB System, R&D Systems), according to manufacturer’s protocol.
Reverse transcriptase–PCR
The total RNAs were isolated from Setd2w/w, Setd2f/w, and Setd2f/f MEFs treated with 4-
hydroxytamoxifen for 0, 3, and 6 days using RNeasy mini kit (Qiagen), and their 
complementary DNAs were synthesized using Supersciprt III reverse transcriptase 
(Invitrogen). The quantities of Setd2 mRNAs were assessed by real-time quantitative PCR 
using specific TaqMan probes (ThermoFisher, Mm01250234_m1) amplifying exon 6, which 
is the region to be deleted by Cre recombination, and a TaqMan Fast Universal master mix 
on QuantStudio Flex Real-Time PCR system (ThermoFisher). The quantities of Setd2 
mRNAs were normalized to those of glyceraldehyde 3-phosphate dehydrogenase, which was 
used as an endogenous control. The following set of conditions were used for each real-time 
reaction: 95°C for 20 minutes followed by 40 cycles of 1 second at 95°C and 20 seconds at 
60°C. The real-time PCR reactions were performed in triplicate twice and quantified using 
the −ΔΔ cycle threshold (CT) method.
Statistics
Densitometry analyses using ImageStudio Ver2.0 were performed on immunoblots of 
H3K36me3 and αTubK40me3 normalized to H3 and αTubulin, respectively. Significance 
was inferred with Tukey’s multiple comparison test. To determine significance of 
micronuclei count or percentage and of mitotic defects from triplicates, we performed a two-
way ANOVA test, which shows significant interactions between samples. We performed 
Student’s t-Test using a paired, two-tailed distribution to determine significance of qRT-PCR 
and micronuclei count in SETD2 knockdown HKC data sets. A reported p-value of less than 
0.05 is considered significant. All analyses were performed using Prism 7 (GraphPad) and 
Excel (Microsoft) software.
Results
SETD2 loss is sufficient to induce genomic instability in normal human kidney proximal 
tubule epithelial cells
Previous studies have linked SETD2 inactivation to genomic instability in RCC utilizing 
tumor-derived analysis (24). We first asked if loss of this tumor suppressor alone was 
sufficient to promote genomic instability in non-tumor kidney epithelial cells. To answer this 
question, and to examine the domain(s) of SETD2 required for maintenance of genomic 
stability in normal kidney epithelial cells, we utilized a cell line generated from 
immortalized normal human kidney proximal epithelial cells (HKC), which retain a normal 
chromosome 3 (Supplementary Fig. S1A). SETD2 was inactivated in the parental HKC line 
(SETD2 −/−), and a series of rescue lines generated by re-expressing SETD2. This panel 
included lines rescued with a fully functional wild-type N-terminal truncated SETD2 
(tSETD2), a tSETD2 catalytically-dead SET domain-mutant (R1625C), and a tSETD2 SRI 
domain-mutant (R2510H). Genomic instability was a prominent feature of SETD2 −/− HKC 
cells expressing empty vector (GFP), catalytically-dead SET domain mutant tSETD2 
R1625C, or the SRI domain mutant tSETD2 R2510H (Fig. 1A). SETD2-deficient cells 
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exhibited a significant increase in both lagging chromosomes and chromosome bridge 
defects (Fig. 1A–C). Thus, as previously seen in RCC-derived 786-0 cells (18), in normal 
kidney epithelial cells both the SET and SRI domains were required to maintain genomic 
stability: an increased incidence of mitotic defects occurred when SETD2 activity is absent 
or when it carries pathogenic mutations in either of these two functional domains.
This genotype-phenotype correlation was extended using micronuclei as a readout of 
genomic instability. Micronuclei were evident as punctate, DAPI-positive structures that 
were also immunoreactive with CREST (anti-centromere) antibody. Only wild-type SETD2 
(tSETD2) could rescue genomic instability in SETD2 −/− HKC cells and reduce micronuclei 
count to normal levels (Fig. 2A). Neither empty vector (GFP), catalytically-dead SET 
domain R1625C, nor SRI domain R2510H SETD2 mutants rescued the increase in 
micronuclei observed in SETD2 −/− HKC. Further, SETD2 −/− HKC cells showed both 
CREST (+) and CREST (−) micronuclei, indicative of entire or fragmented chromosomes 
(Fig. 2B and C). This was also the case in SETD2 −/− HKC cells reconstituted with 
catalytically-dead SET domain (R1625C) and SRI domain (R2510H) tSETD2 mutants (Fig. 
2B and C).
Micronuclei were also a common feature of a panel of ccRCC-derived cell lines, relative to 
ACHN cells, a known wild-type VHL line cytogenetically similar to papillary type renal cell 
carcinomas (25). Single nucleotide polymorphism (SNP) arrays using Log2R and B allele 
frequency score confirmed that all of the ccRCC-derived cells displayed chromosome 3p 
deletion. However, ACHN and proximal tubule kidney epithelial HKC cells (26) retained 
two normal copies of chromosome 3, and had a lower micronuclei count relative to the other 
ccRCC-derived cells (Supplementary Fig. S1A–D).
One question that arises is whether the cells that have experienced genomic instability as a 
result of SETD2 depletion remain in the population and perpetuate these genomic changes 
as potential clonal features furthering the process of tumorigenesis. As an indicator of this 
process, we tested the copy number variation (CNV) of both SETD2 proficient (+/+) and 
SETD2 deficient (−/−) HKC cells. ASCAT-profiles of both HKC cell lines harboring empty 
GFP-containing vector revealed an increase of genomic instability upon SETD2 loss 
characterized by gains and losses of parts of, or entire, chromosomes, supporting the notion 
that changes in SETD2 activity contribute to the genomic instability of tumor cells 
(Supplementary Fig. S2A and B).
Mono-allelic loss of SETD2 is sufficient to abrogate microtubule methylation and increase 
micronuclei formation
In cells lacking SETD2, both microtubule and histone methylation are abrogated (18). To 
determine the impact of reduced SETD2 dosage (mono-allelic loss) on microtubule vs. 
histone methylation, we employed tamoxifen-inducible ER-Cre wild-type Setd2 (w/w), 
heterozygous (w/f) and homozygous (f/f) Setd2 mutant mouse embryonic fibroblasts 
(MEFs). These cells lack the genetic diversity found in cancer cell lines, thus allowing for 
Setd2 alterations to be examined in isolation from other genetic aberrations, and for drawing 
causal associations between mono- and bi-allelic Setd2 loss and genomic stability.
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We first compared the effects of mono- and bi-allelic Setd2 loss on histone (H3K36me3) and 
microtubule (αTubK40me3) methylation. Strikingly, while Setd2w/f MEFs exhibited 
reduction of αTubK40me3, observed in multiple clones whose relative Setd2 mRNA levels 
were shown to be partially reduced compared to those of Setd2w/w MEFs (Supplementary 
Fig. S3A and B), mono-allelic loss of Setd2 caused no change in H3K36me3 levels (Fig. 
3A). Conversely, Setd2f/f MEFs showed a complete loss of both microtubule and histone 
methylation, consistent with complete loss of SETD2 methyltransferase activity (Fig. 3A). 
Thus, mono-allelic SETD2 was haploinsufficient for microtubule, but not chromatin, 
methylation.
To explore the effect of SETD2 mono-allelic loss on genomic stability, we quantitated acute 
chromosomal defects in Setd2w/w and Setd2w/f MEFs following excision of Setd2. Relative 
to Setd2w/w MEFs, Setd2w/f MEFs exhibited evidence for chromosome lagging and 
bridging, the same mitotic defects seen in SETD2-deficient HKC cells, and a significant 
increase in micronuclei (Fig. 3B–D). These data demonstrate that when Setd2 gene dosage is 
reduced by mono-allelic loss of Setd2, this deficit is sufficient to decrease αTubK40me3, 
and cause both mitotic chromosome defects and a statistically significant increase in 
micronuclei. The mitotic phenotype of these cells is similar to that observed with bi-allelic 
loss (18).
As noted above, micronuclei can contain whole chromosomes or acentric chromosome 
fragments, both of which can occur as a result of mitotic defects (lagging and bridging 
chromosomes). Micronuclei of Setd2f/f and Setd2w/f MEFs stained with Hoechst, CENPB 
and CREST also exhibited both CREST (+) whole chromosome and CREST (−) acentric 
chromosome staining (Fig. 4A). Both Setd2f/f and Setd2w/f MEFs showed increased total 
micronuclei number, but homozygous Setd2 MEFs (Setd2f/f) showed a more dramatic 
increase in Hoechst (+) CENPB/CREST (−) micronuclei, containing acentric chromosome 
fragments, compared to Setd2w/f MEFs (Fig. 4B and Supplementary Fig. S4A). Remarkably, 
MEFs with mono-allelic loss of Setd2 (Setd2w/f) showed the most dramatic increase in 
Hoechst/CENPB/CREST (+) micronuclei, suggesting these micronuclei arose 
predominantly from segregation defects involving whole chromosomes (Fig. 4B and 
Supplementary Fig. S4A and B). Importantly, given that MEFs with mono-allelic loss of 
Setd2 (Setd2w/f) were proficient for H3K36me3 histone methylation, these data suggest that 
genomic instability associated with haploinsufficiency is independent of the histone 
methyltransferase activity of SETD2. In agreement with the latter results, partial SETD2 
knockdown (~30% decrease) using shRNA on SETD2-proficient HKC cells further 
demonstrates that reduced SETD2 levels significantly increase micronuclei count 
(Supplementary Fig. S5A–D). Further, as noticed with Setd2w/f MEFs, the same partial 
SETD2 knockdown was sufficient to promote mitotic defects in HKC cells (Supplementary 
Fig. S5E).
Genomic instability is a feature of ccRCC patient-derived tumors
To link the causal associations seen in vitro between mono-allelic loss of SETD2 and 
genomic instability, we utilized tumor cells derived from ccRCC patients to determine if the 
nearly ubiquitous and early loss of chromosome 3p seen in these tumors resulted in loss of 
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genomic stability. Using micronuclei as an indicator for loss of genomic stability, tumor-
derived and adjacent normal kidney cells from five ccRCC patients were stained with DAPI 
(DNA) to quantitate micronuclei, and pan-cytokeratin as a marker for normal epithelial and 
ccRCC cells (Fig. 5). Remarkably, tumor cells from all five ccRCC patient-derived samples 
exhibited a significantly increased frequency of micronuclei (Table 1). The frequency of 
micronuclei in tumor cells ranged from 1.1% to 30%. Micronuclei were detected in only one 
matched normal sample, but in that individual, the frequency of micronuclei was 2-fold 
higher in tumor vs. matched normal cells. The histology of these tumors was confirmed to 
be clear cell, and nuclei of these tumors stained positive for histone methylation 
(Supplementary Fig. S6A), confirming that these tumors retained H3K36 trimethylating 
activity. Additionally, sequencing available tissue from the ccRCC tumor samples identified 
none with deleterious SETD2 mutations (Supplementary Fig. S6B).
To explore if increase in micronuclei count is observed in other types of kidney cancer 
characterized by retaining chromosome 3p, we DAPI stained tumor-derived and adjacent 
normal kidney cells from two papillary RCCs (pRCCs) and two oncocytoma patients and 
quantitated micronuclei. In these patient-derived samples, we found lower micronuclei 
counts compared to those in ccRCC-derived tumor cells (Table 1).
Thus, ccRCC cell lines and ccRCC patient-derived tumor cells exhibit both the genomic 
instability (micronuclei) associated with mono-allelic SETD2 deletion, as a consequence of 
chromosome 3p loss, as well as the dependence on the SRI domain for nonhistone 
methylating SETD2 function. Together, these data demonstrate that micronuclei formation 
occurs with mono-allelic loss of SETD2 in vivo, in line with our in vitro observations, 
pointing to genomic instability and micronuclei as early and common features caused by the 
3p loss in ccRCC.
Discussion
The vast majority (in excess of 95%) of ccRCCs have SETD2 haploinsufficiency as a 
consequence of chromosome 3p loss, and this chromosomal event is widely accepted to be 
an early event in ccRCC transformation (27). Based on our previous and current data, we 
postulate that SETD2 haploinsufficiency plays a crucial role as a driver during early ccRCC 
disease development. In addition, an independent report, using high-resolution profiling of 
H3K36me3 in metastatic ccRCC tumor samples, suggests that decreased SETD2 mRNA 
expression, after mono-allelic loss, is not sufficient to alter SETD2’s histone H3 lysine 
methyltransferase activity (16). Our findings consistently demonstrate SETD2 acting as a 
dual-function methyltransferase, here identifying a scenario in which staged loss of function 
separates these activities. Heterozygosity for SETD2 provides an opportunity for genomic 
instability to promote early disease development, potentially creating conditions permissive 
to the harsher setting of bi-allelic loss, and complete loss of trimethylation functionality. 
Based on these and other data, we propose a stepwise model for loss of SETD2 functionality 
as a driver in ccRCC. First, with the loss of 3p and haploinsufficiency for SETD2 as an early 
event contributing to genomic instability, and upon bi-allelic inactivation, the additional loss 
of H3K36 trimethylating activity (Fig. 6).
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SETD2 is mutated or lost in a growing list of tumors (6–9), and notably mutations in SETD2 
are enriched in chemotherapy refractory pediatric acute lymphocytic leukemia (9, 28). The 
frequency with which these mutations occur in one allele without loss of heterozygosity has 
not been examined in detail. Further, 3p is a commonly deleted genomic region, raising the 
possibility that haploinsufficiency for SETD2 function may be a more common event in 
tumorigenesis than previously considered. It is important to consider, however, that in 
ccRCC tumors (that routinely lose 3p), haploinsufficiency for a number of important 
proteins may be playing a role in permitting tumorigenesis. Indeed, preliminary studies have 
implicated BAP1, another 3p localized gene, as a potential mediator in the haploinsufficient 
state (29). Future studies will need to consider the effect of multigene haploinsufficiency in 
promoting tumorigenesis.
Beyond loss of genomic stability, bi-allelic SETD2 inactivation may contribute to 
tumorigenesis in several ways, in particularly in mediating DNA repair (30). SETD2’s 
expanding function as a methylating enzyme has revealed that, in addition to the H3K36me3 
mark on histones, SETD2 trimethylates lysine 40 on α-tubulin of mitotic microtubules (18) 
and the transcription factor STAT1 (31). In the case of SETD2’s microtubule methylating 
function, failure to trimethylate αTubK40, in the setting of acute Setd2 loss, is accompanied 
by loss of the αTubK40me3 mark from mitotic microtubules, and catastrophic mitotic 
defects (18). These acute effects we previously observed following SETD2 loss were 
unlikely to be accounted for by loss of histone methylation, as conversion of histone 
methylation is considered to be a slow process over several cell divisions, and RNA-seq 
revealed no consistent alterations in gene expression associated with acute SETD2 loss (18). 
Here, we report that mono-allelic SETD2 loss is sufficient to cause genomic instability 
(lagging and bridging chromosomes and micronuclei), which is linked to SRI domain 
defects that uncouple SETD2’s histone methylating from its newly discovered tubulin 
methylating activity. Other targets of SETD2 methylation are emerging, notably STAT1 (31), 
for which the impact of SETD2 haploinsufficiency is unknown. Further, genomic instability 
in human ccRCC tumors that were haploinsufficient for SETD2, but which retained H3K36 
trimethylation, further supports the linkage between microtubule methylation by SETD2 and 
genomic stability. These data also point to micronuclei formation as a cytological tool to 
reveal novel aspects of SETD2 function as a multifunctional tumor suppressor critical to 
genome maintenance.
Micronuclei were identified and described in erythrocytes first by W. Howell (1890) and 
later on by J. Jolly (1905) (32) as small, extranuclear chromatin bodies surrounded by a 
nuclear envelope which originate from acentric chromosome fragments or entire 
chromosomes lagging behind the main chromatin mass during anaphase (33, 34). Today, it is 
accepted that micronuclei represent a faithful cellular indicator of chromosome instability 
(or genomic instability), as high micronuclei frequency is associated with chromosome 
instability observed in many solid tumors and pre-neoplastic lesions (35, 36). Importantly, 
micronuclei have also been documented in primary cancers (33, 35), although ccRCC has 
not been well characterized in this regard. We show that micronuclei are a common feature 
not only among ccRCC-derived cell lines, but more importantly among ccRCC patient-
derived tumors. Considering the typical low mitotic rate of primary RCC tumors, the 
Chiang et al. Page 12













accumulations of micronuclei at the rates we observed implicate chromosome instability as a 
major driver of ccRCC tumorigenesis.
In showing that SETD2 haploinsufficiency, and partially reduced levels of SETD2, are 
sufficient to initiate a wide range of mitotic defects resulting in lagging chromosomes and 
micronuclei formation, our data further underscore a much more complex role for SETD2 in 
genome maintenance than previously appreciated. While some of the more dramatic 
examples may represent mitotic failures, the persistence of micronuclei implies that some 
aberrant mitoses are permitted, possibly as a result of a failed checkpoint. In cells lacking 
SETD2, we were able to show evidence of an unstable genome, although this model does 
not fully address the haploinsufficient state. The bypassed checkpoint allowing these cells to 
persist remains an object of future investigation. In this regard, the shared genomic 
instability phenotype seen with SETD2 haploinsufficiency and SRI-domain defects that 
abrogate microtubule but not histone methylation argues that maintenance of genomic 
stability by SETD2 is linked to its function as a microtubule methyltransferase. These data 
also suggest αTubK40 trimethylation is more sensitive to SETD2 stoichiometry fluctuations 
than H3K36 trimethylation. The effect of SETD2 haploinsufficiency on any other targets is 
not known. These data strongly support the notion of αTubK40me3 playing a specialized 
role in maintaining genomic stability during mitosis. Dissecting the tubulin dynamics that 
govern this process, and the specialized role of SETD2 and the SRI domain in regulating 
αTubK40 methylation will be an important future goal.
It is now well accepted that the main drivers of cancer are not limited to highly penetrant 
dominant and recessive mutations, but also include heterozygous losses giving rise to 
haploinsufficiency states (37). There is an ever-increasing number of tumor suppressor genes 
known to display haploinsufficiency, such as PTEN and p53 (among others), with some 
pathways showing a higher tendency to dosage sensitivity than others (37–39). Another 
example of haploinsufficiency in cancer progression is PERK, an endoplasmic reticulum 
transmembrane protein kinase, displaying pro-tumorigenic activity in melanomas harboring 
activated BrafV600E mutation. However, deletion of one allele of PERK is permissive for 
BrafV600E–dependent transformation, while excision of both alleles did not cooperate with 
BrafV600E in melanoma tumorigenicity (40). Interestingly, PERK mutations decreasing its 
activity are seen at a 7% frequency (40). Therefore, our compelling results showing SETD2 
dose-dependent methyltransferase activity are in line with the work previously done in other 
cancer types, and demonstrate a crucial, and previously unappreciated, role of SETD2 
haploinsufficiency caused by 3p loss in progression of ccRCC.
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Loss of a single allele of a chromatin modifier plays a role in promoting oncogenesis, 
underscoring the growing relevance of tumor suppressor haploinsufficiency in 
tumorigenesis.
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Figure 1. SETD2 loss and pathogenic mutations in SET and SRI domains promote mitotic 
defects
A, Mitotic cells were plotted for the entire tSETD2 HKC panel. Percentage (%) of cells 
undergoing normal (light gray) mitosis, or displaying multipolar spindle (orange), 
chromosome bridging (dark gray), or chromosome lagging defects are represented. B, 
Representative immunofluorescence images of SETD2 −/− HKC GFP, SETD2 −/− HKC 
tSETD2-R1625C, and SETD2 −/− HKC tSETD2-R2510H co-stained with DAPI 
(chromosomes; blue) and CREST (centromeres; magenta) are shown. Light blue arrowheads 
indicate lagging chromosome. Light gray arrowhead indicates chromosome bridge. Bar: 
10um. C, Quantitation of cells undergoing normal mitosis or displaying lagging 
chromosome, bridging, or multipolar spindle defects for all tSETD2 HKC panel.
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Figure 2. SETD2 loss and pathogenic mutations in SET and SRI domains promote genomic 
instability
A, Micronuclei quantitation from entire tSETD2 HKC panel. **, P < 0.01; ****, P < 
0.0001; ns, no statistical significance observed. B, Representative immunofluorescence 
images of SETD2 −/− HKC GFP, SETD2 −/− HKC tSETD2-R1625C, and SETD2 −/− HKC 
tSETD2-R2510H co-stained with DAPI (nuclei and micronuclei; blue) and CREST 
(centromeres; magenta) are shown. Yellow arrowheads: DAPI/CREST (+) micronuclei. Red 
arrowheads: DAPI (+) CREST (−) micronuclei of selected cells magnified (3x digital zoom) 
in each inset. C, Quantitation of CREST (+) and CREST (−) micronuclei per 100 cells for 
the entire tSETD2 HKC panel.
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Figure 3. Mono-allelic SETD2 inactivation is sufficient to lower αTubK40me3 and promote 
micronuclei formation
A, Western blot analysis of indicated proteins on tamoxifen-treated Setd2w/w, Setd2w/f, and 
Setd2f/f MEFs at three different time points (0; 3; and 6 day). Light and dark exposures of 
SETD2’s blots are shown. Histone H3 and αTubulin (αTub) are used as loading controls. B, 
Representative immunofluorescence images of six-day treated (6d) and non-treated 
Setd2w/w, and Setd2w/f MEFs co-stained with αTubulin (green) and Hoechst (nuclei and 
micronuclei; blue). Framed cells magnified (3x digital zoom) and Hoechst images shown in 
insets depicting micronuclei and nuclei. Bar: 100um. C, Micronuclei quantitation from six-
day treated and non-treated Setd2w/w, and Setd2w/f MEFs shown in panel B. ****, P < 
0.0001. D, Representative immunofluorescence images of three-day (3d) treated and non-
treated Setd2w/f MEFs co-stained with αTubulin (green) and Hoechst (blue) showing 
lagging chromosome (yellow arrowhead) and chromosome bridge (red arrowhead). Bar: 
10um.
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Figure 4. SETD2 haploinsufficiency promotes genomic instability
A, Representative immunofluorescence images of tamoxifen-treated and non-treated Setd2f/f 
and Setd2w/f MEFs co-stained with Hoechst (nuclei and micronuclei), CENPB and CREST 
(centromeres) are shown. Yellow arrows point to Hoechst/CENPB/CREST (+) staining. B, 
Percentage (%) of micronuclei + cells. Quantitation of CREST (+) (black) and CREST (−) 
(white) micronuclei within micronuclei (+) cells for Setd2f/f and Setd2w/f MEFs.
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Figure 5. Micronuclei detected in ccRCC patient-derived tumors
Immunofluorescence images of patients 99 and 126 co-stained with DAPI (nuclei and 
micronuclei; magenta) and cytokeratin (epithelial and tumor cells; green). Yellow boxes 
enclose micronuclei. Bar: 5um.
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Figure 6. Proposed stepwise model of loss of SETD2 functionality
We postulate that SETD2 haploinsufficiency during early stages of ccRCC plays a crucial 
role in the disease progression by reducing αTubK40me3 levels and thus causing genomic 
instability. At later stages, SETD2 haploinsufficiency potentially creates conditions 
conducive to the harsher setting of bi-allelic loss with associated complete loss of 
trimethylating activity. Yellow rectangle: wild-type SETD2 gene. Red rectangle: mutated 
SETD2 gene.
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Table 1
Micronuclei are a feature of ccRCC patient-derived tumors
Quantifying histologic grade, H3K36me3 status, percentage of micronucleated tumor and normal cells 
according to histology and predicted status of chromosome 3p. Patient 126, and nonclear cell tumors without 
normal match.
Patient ID Tumor type Histologic Grade % micronucleated tumor cells % micronucleated normal cells
Chr 3p Loss
54 ccRCC G3 1.14 (1/88) 0.00 (0/69)
55 ccRCC G2 2.67 (2/75) 0.00 (0/59)
91 ccRCC G2 3.09 (3/90) 1.59 (2/126)
99 ccRCC G4 1.11 (1/90) 0.00 (0/88)
126 ccRCC G2 30.3 (10/33) No matched normal
No Chr 3p Loss
74 pRCC G2 0.00 (0/248) No matched normal
77 pRCC G2 0.49 (3/608) No matched normal
65 Oncocytoma N.R. 0.28 (1/352) No matched normal
87 Oncocytoma N.R. 0.20 (1/505) No matched normal
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